Garde Capital’s Cogent Biosciences COGT Stock Holding History

Garde Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10	Closed	-$72	–	361
2025 Q2	$72	Hold	10	–	–	﹤0.01%	822
2025 Q1	$60	Buy	+10	New	+$78	﹤0.01%	815

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Garde Capital's COGT Position: Q3 2025 in Review

Garde Capital sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 10 shares — an estimated $72 sold.

Garde Capital first reported a position in COGT in Q1 2025 and held it in 2 quarters. The position peaked at $72 in Q2 2025. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

Garde Capital reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 10 Cogent Biosciences shares in Q3 2025, an estimated $72.
Garde Capital first reported a position in Cogent Biosciences in Q1 2025 and held it in 2 quarters.
Garde Capital's Cogent Biosciences position peaked at $72 in Q2 2025.
195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.